DEFR14A: Alumis and ACELYRIN Announce Merger Agreement, Creating Combined Biopharmaceutical Company

Alumis and ACELYRIN have agreed to merge, forming a combined entity focused on developing transformative medicines, with ACELYRIN stockholders receiving 0.4814 shares of Alumis for each ACELYRIN share.

Summary

• Alumis and ACELYRIN have entered into a merger agreement where Arrow Merger Sub, Inc. will merge into ACELYRIN, with ACELYRIN becoming a wholly-owned subsidiary of Alumis.
• ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock they own.
• Alumis stockholders will continue to own their existing shares.
• Following the merger, Alumis stockholders are expected to own approximately 52% of the combined company, while ACELYRIN stockholders are expected to own approximately 48%, calculated on a fully diluted basis as of January 31, 2025.
• Special meetings for both Alumis and ACELYRIN stockholders are scheduled for May 13, 2025, to vote on the merger-related proposals.
• The Alumis board recommends voting FOR the Alumis stock issuance proposal and FOR the Alumis adjournment proposal.
• The ACELYRIN board recommends voting FOR the ACELYRIN merger proposal and FOR the ACELYRIN adjournment proposal.
• The merger is expected to close in the second quarter of 2025, pending stockholder and regulatory approvals.
• The document also discusses the background of the merger, reasons for the merger, opinions of financial advisors, voting agreements, termination fees, and other related matters.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the potential benefits and strategic rationale. However, it also acknowledges the risks and uncertainties involved, resulting in a moderately positive sentiment score.

Positives

• The merger creates a combined company with a broader pipeline and greater financial resources.
• The combined company is expected to have a strong cash position, extending its runway into 2027.
• The merger diversifies Alumis drug-discovery risk profile and improves operational capabilities and efficiencies.
• The Alumis board believes the exchange ratio is financially attractive in light of Alumis standalone value.
• The addition of two ACELYRIN board members to the Alumis board adds relevant expertise and maintains continuity.
• The merger is expected to qualify as a tax-free reorganization.

Negatives

• Current Alumis stockholders will have a reduced ownership interest and voting power in the combined company after the Merger.
• The Exchange Ratio is fixed and will not be adjusted based on the market price of Alumis common stock, so the consideration at the closing of the Merger may have a greater or lesser value than at the time the Merger Agreement was signed.
• The combined company may fail to realize the anticipated benefits of the Merger.
• Alumis expects to incur substantial costs and expenses related to the integration of the combined company upon the consummation of the Merger, which costs and expenses are difficult to estimate accurately.

Risks

• The Merger may not be completed on the terms or timeline currently contemplated, or at all.
• Litigation relating to the Merger, if any, could result in an injunction preventing the completion of the Merger and/or substantial costs to Alumis and ACELYRIN.
• The pendency of the Merger could adversely affect the business and operations of Alumis and ACELYRIN.
• Failure to attract, motivate and retain executives and other key employees could diminish the anticipated benefits of the Merger.
• If the combined company is unable to compete effectively, the results of operations of the combined company will be materially and adversely affected.
• The combined companys quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts or any guidance it may publicly provide, each of which may cause Alumis common stock price to fluctuate or decline.
• If the Merger does not qualify as a reorganization under Section 368(a) of the Code, U.S. holders of ACELYRIN common stock may be required to pay additional U.S. federal income taxes.

Future Outlook

The combined company will focus on developing transformative medicines, with multiple development milestones expected in 2025 and 2026.

Management Comments

• Martin Babler, President and Chief Executive Officer of Alumis Inc., looks forward to the successful Merger of Alumis and ACELYRIN.
• Mina Kim, Chief Executive Officer of ACELYRIN, Inc., looks forward to the successful Merger of Alumis and ACELYRIN.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to diversify pipelines, share resources, and enhance long-term growth potential.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical industry often pursue mergers to expand their pipelines and reduce risk.
• The exchange ratio and termination fee are within typical ranges for similar transactions in the sector.
• The pro forma ownership split is subject to market fluctuations and may be compared to other recent mergers in the industry.

Related Party Transactions

• The document discloses relationships and transactions with related parties, including Foresite Labs and certain directors and executive officers.

Stakeholder Impact

• Shareholders of both companies will be impacted by the merger, with ACELYRIN shareholders receiving Alumis stock and Alumis shareholders experiencing dilution.
• Employees of both companies may be affected by potential restructuring and integration efforts.
• Customers and patients may benefit from the development of new and improved therapies.

Next Steps

• Alumis and ACELYRIN stockholders will vote on the merger-related proposals on May 13, 2025.
• The companies will work to obtain necessary regulatory approvals.
• The companies will continue to integrate their operations and develop their product pipelines following the merger.

Key Dates

Keywords

merger, ACELYRIN, Alumis, stockholders, common stock, agreement, biopharmaceutical, Exchange Ratio, clinical trials, regulatory approval